Integrin-targeted paclitaxel nanoliposomes for tumor therapy

Area of Science:

• Nanomedicine
• Drug Delivery
• Oncology

Background:

• Paclitaxel has poor solubility and lacks tumor specificity.
• Tumor vasculature overexpresses alphaV integrins, making them a target for drug delivery.

Purpose of the Study:

• To develop a neovessel-targeted PEGylated liposomal formulation of paclitaxel.
• To improve paclitaxel solubility and target tumor vasculature using RGD peptides.

Main Methods:

• Formulation of PEGylated liposomes encapsulating paclitaxel.
• Integration of RGD-containing peptides to target alphaV integrins on tumor neovessels.
• In vitro drug release studies, plasma distribution, cellular uptake, and in vivo tumor growth inhibition in mice.

Main Results:

• Liposomes had particle size <100 nm and drug entrapment efficiency >95%.
• The formulation showed a lower in vitro release rate and improved plasma paclitaxel concentration post-injection compared to Taxol.
• Enhanced cellular uptake and reduced tumor microvessel density were observed in targeted liposome-treated groups.

Conclusions:

• RGD-based targeting enhances tumor-specific recognition of nanocarriers.
• Neovessel-targeted PEGylated paclitaxel liposomes represent a promising strategy for cancer therapy.